Trial Profile
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2019
Price :
$35
*
At a glance
- Drugs Aminolevulinic acid (Primary)
- Indications Glioma
- Focus Diagnostic use
- 21 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 09 Apr 2014 New trial record